First Time Loading...

Aligos Therapeutics Inc
NASDAQ:ALGS

Watchlist Manager
Aligos Therapeutics Inc Logo
Aligos Therapeutics Inc
NASDAQ:ALGS
Watchlist
Price: 0.846 USD 9.87%
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one ALGS stock under the Base Case scenario is 1.246 USD. Compared to the current market price of 0.846 USD, Aligos Therapeutics Inc is Undervalued by 32%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALGS Relative Value
Base Case
1.246 USD
Undervaluation 32%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.1
P/S
P/S
Price to Sales
4.1
vs History
55
vs Industry
70
Median 3Y
5.5
Median 5Y
4.6
Industry
8.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.7
Industry
26.2
Forward
-1
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.8
Industry
22.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-0.7
Median 5Y
-0.8
Industry
21.3
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
42
vs Industry
69
Median 3Y
0.6
Median 5Y
0.6
Industry
2.5
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
85
Median 3Y
-3.7
Median 5Y
-4.6
Industry
7.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
0.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.8
vs History
31
vs Industry
16
Median 3Y
0.6
Median 5Y
0.6
Industry
4.4
Forward
0.7
More Details
0.8
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.8
vs History
26
vs Industry
15
Median 3Y
0.6
Median 5Y
0.6
Industry
4.3
Forward
0.6
More Details
0.9
EV/OCF
EV/OCF
Enterprise Value to OCF
0.9
vs History
28
vs Industry
18
Median 3Y
0.7
Median 5Y
0.6
Industry
5.4
More Details
0.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.9
vs History
28
vs Industry
14
Median 3Y
0.7
Median 5Y
0.6
Industry
3.2
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
74
Median 3Y
-3.8
Median 5Y
-3.2
Industry
5
More Details

Multiples Across Competitors

ALGS Competitors Multiples
Aligos Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Aligos Therapeutics Inc
NASDAQ:ALGS
64m USD 4.1 -0.7 0.8 0.8
US
Abbvie Inc
NYSE:ABBV
286B USD 5.3 59.3 12.9 19.7
US
Amgen Inc
NASDAQ:AMGN
167.1B USD 5.9 24.9 17.9 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.8B USD 10.4 28.3 22.7 23.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
102.9B USD 7.8 26 17.5 19.2
AU
CSL Ltd
ASX:CSL
133.2B AUD 6.2 35.4 21.5 26.6
US
Gilead Sciences Inc
NASDAQ:GILD
80.4B USD 2.9 165.9 6.7 8.7
US
Moderna Inc
NASDAQ:MRNA
47.3B USD 7 -10.1 -10.9 -9.3
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.2B USD 3.2 26.8 13.7 17.2
KR
Celltrion Inc
KRX:068270
39.2T KRW 18 73.1 44.7 61.6
P/E Multiple
Earnings Growth
US
Aligos Therapeutics Inc
NASDAQ:ALGS
Average P/E: 55
Negative Multiple: -0.7 		N/A
US
Abbvie Inc
NYSE:ABBV
59.3
405%
US
Amgen Inc
NASDAQ:AMGN
24.9
82%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.3
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
26
46%
AU
CSL Ltd
ASX:CSL
35.4
84%
US
Gilead Sciences Inc
NASDAQ:GILD
165.9
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -10.1 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
26.8
154%
KR
Celltrion Inc
KRX:068270
73.1
105%

See Also

Summary
ALGS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALGS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALGS stock valuation using valuation multiples.
Wall Street Estimates
ALGS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALGS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.